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Since the beginning of the United States AIDS epidemic in the early 1980s, the medical 
community has overcome significant challenges in the diagnosis and treatment of Human 
Immunodeficiency Virus (HIV) infections. Many advancements in suppressing HIV viral loads 
and maintaining healthy immune system function in HIV positive patients have been achieved 
with antiretroviral therapy (ART). Moreover, these drugs have been shown to be effective for 
preventing HIV infections. Once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) has 
been approved by the FDA for this purpose. The availability of this preventive therapy, commonly 
known as preexposure prophylaxis (PrEP), necessitates educating at-risk patient populations about 
its prophylactic benefits.  In order to select appropriate candidates for PrEP prophylaxis, its 
efficacy in different at-risk populations needs to be determined.  This investigation examines 
disparities in PrEP’s efficacy among at-risk groups and proposes explanations that may guide the 
medical provider in offering PrEP therapy to patients who could benefit. Additionally, current 
clinical trials and studies with alternative PrEP options will be explored. 














According to the CDC’s 2015 HIV surveillance data, in the United States approximately 
40,000 individuals seroconverted to an HIV positive status and the prevalence of HIV reached 
nearly 1 million people. Notwithstanding this staggering number, the percentage of individuals 
who became HIV seropositive declined by eight percent from the years 2010 to 2015.1 Improved 
preventative and therapeutic measures have played a pivotal role in reducing HIV seroconversion 
and infections. Despite advancements in HIV treatment and prevention, preventative strategies 
including preexposure prophylaxis (PrEP) are underutilized across many medical settings. Of 
particular concern are the stigma surrounding potential HIV exposures and the lack of awareness 
about PrEP, both of which can impede the clinician’s efforts to educate patients who are at high 
risk of HIV seroconversion.  
In order to select candidates for prevention of HIV seroconversion, persons at increased 
risk of HIV exposure need to be identified. According to the CDC, gay and bisexual men account 
for 67% of the approximately 40,324 new HIV diagnoses made in the United States in 2016.2 
Furthermore, receptive anal intercourse has a 13-fold higher risk of transmitting HIV than insertive 
anal intercourse.3 Although male-to-male sexual contact puts gay and bisexual men as the 
population at the highest risk of HIV seroconversion, other populations such as heterosexuals, 
serodiscordant couples, and IV drug users are also at increased risk. Unprotected receptive anal 
intercourse accounts for approximately 138 infections per 10,000 exposures, but needle-sharing 
injection drug use accounts for approximately 63 infections per 10,000 exposures, while receptive 
and insertive penile-vaginal intercourse each account for 8 infections and 4 infections per 10,000 
exposures respectively.5 All of these high-risk populations may benefit from preventative 
measures against HIV seroconversion. Therefore, medical providers should counsel patients 




accordingly. Besides educating patients about safe-sex practices, clinicians can offer preexposure 
prophylaxis with anti-retroviral agents.  
Antiretrovirals (ARV) have been shown to suppress HIV viral loads, which results in viable 
CD4 T-lymphocyte counts and healthy immune system function in HIV infected patients. In 
addition, when used prophylactically these medications have been shown to prevent HIV infection 
in high-risk individuals. Truvada (emtricitabine/tenofovir disoproxil fumarate) was initially 
approved in 2004 by the Food and Drug Administration (FDA) to be used in combination with 
other ARVs in an HIV treatment regimen.4 After its success in HIV therapy was demonstrated, 
this formulation of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) was studied 
and approved by the FDA on July 16th, 2012 for preexposure prophylaxis (PrEP) treatment in HIV 
negative patients who are at high risk of HIV seroconversion.3 When taken appropriately, PrEP 
was shown to be effective for prevention of HIV seroconversion in at-risk populations. Experience 
with PrEP has primarily been in the men who have sex with men (MSM) population. Although 
PrEP’s overall efficacy in at-risk patients has been proven, further investigation is needed to show 
its usefulness in specific at-risk groups such as heterosexuals, IV drug users, and serodiscordant 
couples. In order to optimize PrEP’s effectiveness, it is important to understand its potential 
benefits and limitations across all at-risk populations.  
Animal Studies and Pharmacokinetics 
 Initial studies in animals and humans using tenofovir disoproxil fumarate (TDF) showed 
that a single ARV was inadequate for prophylactic protection,6-7 although it did have a good safety 
profile in humans. The need for two drug combinations for HIV prophylaxis was evident since a 
single ARV was ineffective.  




The hypothesis of utilizing a two-drug regimen for HIV prophylaxis was promising and 
thus further explored in animal models. Chinese rhesus macaques were challenged with simian 
HIV to determine if using a two-drug combination compared to a single drug agent or no drug at 
all had a better prophylactic effect against HIV transmission. These monkeys were either untreated 
(control group) or treated; the treatment groups received tenofovir disoproxil fumarate (TDF), 
emtricitabine (FTC), or a compounded TDF-FTC. The results revealed that monkeys treated with 
a subcutaneous dose of FTC or a human equivalent dose of TDF-FTC, had a 3.8- and 7.8-fold 
decreases in seroconversion rates respectively, compared to the untreated monkeys.8 This evidence 
confirmed that two agents provided better prophylaxis than either a single agent or no ARV.  
 Success of the two-drug regimen in animals prompted human trials. The pharmacokinetic 
profiles of ARVs in humans, in particular, their tissue penetrance, are especially important with 
regards to using these drugs as a prophylactic option because some human tissues are exceptionally 
vulnerable to transmission of HIV. In 2011, male and female volunteers were studied to determine 
the concentrations of TDF and FTC in blood plasma as well as in mucosal tissues, particularly in 
vulnerable tissues like rectal and vaginal mucosa. Despite a small sample size, 100-fold higher 
concentrations of TDF were found in rectal tissues compared to vaginal/cervical tissues.9 Given 
these results, PrEP use in certain groups may be more or less effective depending upon the tissue 
exposed to the virus. After pharmacokinetic studies, PrEP research shifted to human participants 
for FDA approval.  
 PrEP was approved after many noteworthy studies examined its safety and efficacy for 
preventing HIV infection in groups that are at particularly high risk of HIV seroconversion, such 
as the MSM population, transgender women who have sex with men, high-risk heterosexual men 




and women, and IV drug users. Clinical studies were necessary to determine PrEP’s efficacy across 
these at-risk groups.  
Men Who Have Sex with Men and PrEP: iPrEx Trial, ANRS Ipergay Study, PROUD study 
A multinational, double-blind placebo-controlled known as the Preexposure Prophylaxis 
Initiative, or the iPrEx trial, evaluated whether a once-daily compounded regimen of TDF-FTC 
would provide adequate chemoprophylactic protection against HIV in the MSM and transgender 
women who have sex with men populations. A total of 2499 HIV seronegative MSM and 
transgendered women who have sex with men were assigned to either the treatment group with 
TDF-FTC, or the placebo-control group. A comprehensive package of protection was also 
provided to these patients through monthly visits. These visits included information on safe-sex 
practices, condoms, HIV testing, and treatment of other STIs. Serum drug levels were also 
measured in each of the subjects to determine adherence. The subjects were followed for a total of 
3324 person-years. Results showed a 44% reduction in HIV seroconversion in the treatment group 
compared to placebo. Although this value was lower than what the researchers predicted, the 
discrepancy was partly explained by low adherence. In the subjects who had detectable serum drug 
levels, risk of HIV seroconversion decreased by 92% compared to those subjects with poor or 
undetectable levels who evidently did not adhere properly to the drug regimen. These findings 
highlighted that PrEP compliance correlates with higher efficacy of the intended prophylactic 
effect.10  
Given the importance of adherence to PrEP, a study to address PrEP’s efficacy with on-
demand use rather than once daily dosing was conducted. The ANRS Ipergay study examined 
whether using PrEP on-demand, which means taking the drugs only as needed for risky sexual 
behaviors, would still provide prophylactic protection in the MSM cohort. In this double-blind, 




randomized placebo-controlled study, on-demand use conditions were met when the treatment 
group took two doses of TDF-FTC 2 to 24 hours prior to sexual contact, and then took additional 
doses at 24 and 48 hours after the sexual contact. Risk was reduced by 86% in the treatment group 
compared to the placebo group.11 Although these findings were promising, they were limited 
because the number of on-demand doses taken could not exceed the maximum total daily dose 
regardless of the number of sexual encounters in a day. An open-label study approximating real-
life application of PrEP could correct this limitation.  
PROUD was the first open-label, randomized controlled trial for PrEP, which was designed 
to test efficacy in real-life situations in the MSM population. Five hundred and forty-four male 
participants who had condom-less anal intercourse in the previous 90 days were enrolled in the 
study across 13 sexual health clinics in England. Initially, the study called for an immediate 
treatment group and a deferred treatment group, but all of those assigned to the deferred group 
were eventually moved to the treatment group after evidence in concurrent studies showed PrEP 
to be efficacious in HIV prevention. Findings confirmed that daily TDF-FTC provided the best 
protection against HIV seroconversion, eliminating the concerns of PrEP utilization in the MSM 
population in real-world settings.12 
While PrEP is effective in MSM, the population at the highest risk of seroconversion, other 
populations are also at risk, such as heterosexuals and IV drug users. These groups could 
potentially benefit from PrEP, leading to additional research with PrEP in these patient 
populations.  
Heterosexuals and PrEP: Partners PrEP Trial, TDF2 Study, and FEM-PrEP Study 
The Partners PrEP Trial addressed the use of antiretroviral therapy (ART) for preventing 
HIV in heterosexual serodiscordant couples, otherwise known as discordant serostatus, which 




means one partner was HIV positive and the other is HIV negative. A sample of 4747 couples was 
enrolled and then randomly assigned to treatment with TDF, TDF-FTC, or placebo. 
Seroconversion occurred in a total of 82 subjects. 17 subjects seroconverted in the TDF group, 13 
in the TDF-FTC group, and 52 in the placebo group, equating to a 67% and 75% decrease in 
incidence of HIV seroconversion in the TDF and TDF-FTC groups, respectively.13 These results 
were promising; however, further studies were needed in order to confirm that these prophylactic 
treatments were efficacious in this group.  
Additional research in sexually active heterosexuals at risk for HIV seroconversion was 
assessed in the TDF2 study. This phase III, randomized, placebo-controlled clinical trial was 
conducted in different cities in Botswana, which has the world’s second highest HIV 
seroconversion rate.14 This trial randomly selected 1219 men and women to be assigned to either 
the TDF-FTC treatment group or to the placebo group. Unfortunately, due to poor retention of the 
subjects, it was stopped early. The researchers decided to perform a modified analysis of the data 
they obtained, which showed an overall efficacy of 62.2% of TDF-FTC in preventing HIV 
seroconversion when used in conjunction with a package of other HIV prevention tools.14 Despite 
the poor subject retention, evidence in this study suggests that PrEP is effective. Nonetheless, 
further studies are necessary to confirm these findings.  
Since previous studies did not show successful HIV prevention in at-risk heterosexual 
women, the 2012 FEM-PrEP study specifically tested PrEP’s efficacy in this population. Across 
Kenya, South Africa, and Tanzania, 2129 women were enrolled. These women were randomly 
assigned to receive once daily TDF-FTC (the treatment group), or a once daily placebo (the control 
group). HIV seroconversion was detected in 33 women in the TDF-FTC group and in 35 women 
in the placebo group, with an incidence rate of 4.7% and 5.0% respectively15. This study was also 




terminated early because PrEP was not proven to be efficacious in preventing HIV infection in 
these women. The data did not show efficacy in once daily FTC-TDF, but detectable serum drug 
levels were only present 28% to 37% at the time the specimens were collected, revealing that a 
lack of adherence may have explained the lack of efficacy. Although adherence to prophylaxis is 
vital for prevention, the pharmacokinetics of TDF-FTC limit drug concentrations in vaginal and 
cervical tissues as compared to rectal tissues. This discrepancy in tissue drug concentration must 
be considered when determining whether PrEP is appropriate for use in heterosexual females who 
engage in unprotected coitus.  
IV Drug Users and PrEP: The Bangkok Tenofovir Study 
 Though sexual transmission of HIV is of upmost concern, intravenous drug use and needle 
sharing put individuals at high-risk of HIV seroconversion. According to the Center for Disease 
Control, people who injected drugs (PWID) accounted for 9% of the nearly 40,000 new HIV 
diagnoses in 2016.16 Even though this group accounts for a smaller percentage of new HIV 
diagnoses, PrEP could still serve as a beneficial strategy. The 2013 Bangkok Tenofovir study, a 
phase III, randomized, double-blind, placebo-controlled trial examined whether PrEP would 
reduce the risk of HIV seroconversion in PWID. The 2413 participants were enrolled across 17 
drug-treatment clinics in Bangkok, Thailand; 1204 participants in the treatment group were 
instructed to take 300mg of once daily tenofovir disoproxil fumarate (TDF), and 1209 participants 
belonged in the placebo control group. Seventeen subjects in the TDF group seroconverted to an 
HIV positive status, while 33 seroconverted in the placebo-control group, equating to a 48.9% 
reduction in HIV incidence.17 Whether those that seroconverted did so from their IV drug use or 
from sexual intercourse was a limitation of this study. Nonetheless, PWID are at significant risk 
of seroconverting and PrEP should be offered to this population.   




Side Effects and Adverse Events of PrEP 
 Currently, Once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) is approved 
for the use of PrEP in high-risk patients. In the iPrEx study, nausea was reported in 22 patients in 
the treatment group compared to 10 patients in the placebo group. Additionally, unintentional 
weight loss of 5% or more was seen in 34 versus 19 patients of the treatment and placebo groups 
respectively10. However, in the Partners PrEP trial no statistical differences were found in side 
effects including fatigue, nausea, abdominal pain, headaches, or diarrhea13. Future research may 
find drugs for HIV prophylaxis that have fewer side effects. Nonetheless, PrEP currently has only 
limited and mostly mild adverse effects in comparison to the protective value it provides. When 
prescribing PrEP, not only is understanding its side effects and adverse events important in 
providing the proper patient education but also specific precautions should be considered.  
 Severe adverse reactions can occur with PrEP, for which reason cautionary measures 
should be instituted. Truvada, which contains tenofovir disoproxil fumarate (TDF) and 
emtricitabine (FTC), requires evaluation of a patient’s renal function before and during therapy. 
TDF is excreted extensively by the kidneys and can be nephrotoxic. Poor renal function could lead 
to toxic levels of the drug. Serum creatinine values can be used to determine whether a patient is 
an appropriate candidate for PrEP and should be monitored periodically throughout therapy.18 In 
the iPrEx trial, only one subject was dropped from the study due to an increase in serum creatinine 
compared to no dropouts in the placebo group.10 In the Partners PrEP trial, six subjects were 
dropped from the study due to an increase in their serum creatinine compared to no dropouts in 
the placebo group.13  
Another adverse reaction of TDF is loss of bone mineral density (BMD). Over the course 
of a year’s therapy, TDF can cause a 1-3% decreased in BMD compared to other NRTIs.19 In the 




iPrEx trial, 13% of the participants lost more than 5% BMD of the spine compared to 6% of the 
participants in the placebo group.10 Bone fractures were noted in 1.7% of the treatment group in 
the iPrEx trial compared to 1.4% in the placebo group.10 In the Partners PrEP trial, 0.8% of the 
treatment group experienced bone fractures compared to 0.6% in the placebo group.13 Although 
BMD is affected, the benefits of PrEP exceed these relatively insignificant changes. Nonetheless, 
this adverse effect should be taken into consideration for those with small stature or preexisting 
osteomalacia.  
Despite the current adverse effects of PrEP on the kidneys and bone mineral density, 
healthy individuals typically tolerate the regimen well and do not require discontinuation due to 
these adverse effects. Other antiretrovirals and regimens are being investigated for the purpose of 
limiting the number of adverse events and removing the daily pill burden while still providing 
prophylactic HIV protection.  
The Future of PrEP 
Descovy (emtricitabine/tenofovir alafenamide fumarate) is currently FDA approved for 
the treatment of HIV. Similar to Truvada, it contains two NRTIs and should be used in 
combination with other HIV medications to achieve viral suppression and maintain healthy CD4 
counts. The differences between the two antiretrovirals are that Descovy contains the NRIT 
known as tenofovir alafenamide fumarate (TAF) and Truvada contains an NRTI known as 
tenofovir disproxil fumarate (TDF). Compared to TDF, TAF has less adverse renal effects and 
leads to less bone mineral density loss.19 Given that less adverse effects are observed with 
Descovy compared to Truvada, the DISCOVER study was initiated to determine if Descovy 
could provide prophylactic protection similar to Truvada.  




DISCOVER, a current phase III randomized double-blind study that began in September 
2016, is comparing Descovy against Truvada for safety and efficacy in preventing HIV 
seroconversion in the MSM population. This study has 5400 participants who were randomized 
into a group that is either being treated with Truvada (TDF-FTC) plus a placebo pill or treated 
with Descovy (TAF-FTC) plus a placebo pill20. The participants will be blinded for at least 96 
weeks, after which they will have the option to be unblinded and decide whether to continue in an 
open label extension of the Descovy regimen for another 48 weeks. HIV status, bone mineral 
density, serum creatinine, and side effects that the subjects experience will be monitored. This trial 
is expected to be completed in July of 2021. If proven to be efficacious, Descovy could be the 
new first-line therapy for PrEP. However, it still bears the pill-burden of a once-daily regimen.  
 In order to improve medication adherence issues and decrease overall pill burden, other 
routes of PrEP administration are being investigated. Injectable routes of administering PrEP using 
Cabotegravir (CAB), an integrase strand transfer inhibitor (INSTI), are being tested. CAB showed 
excellent safety, tolerability, and acceptable pharmacokinetics in the HPTN 077 trial, a phase 2a 
clinical trial to assess the safety and efficacy of the injectable long-acting CAB.21 Common side 
effects in this study were a mild injection site reaction which caused some patients to drop out of 
the study. The drug reached the appropriate drug levels in the treatment group that received an 
injectable regimen of 600mg every 8 weeks after an initial 4 week loading dose21. Currently, the 
HPTN 083 trial is underway that is comparing injectable CAB to the currently FDA approved 
PrEP, oral Truvada, in the MSM population.22 Recruitment for this study is currently ongoing 
and its completion date is yet to be determined. If the injectable CAB is proven to be as efficacious 
as Truvada, it could become an option for at-risk individuals, especially those who have difficulty 
with adhering to a daily regimen.  





Evidence shows that Truvada for PrEP is efficacious if used in high-risk populations for 
preventing HIV seroconversion, particularly in the MSM population. Although some studies did 
not confirm its efficacy, a lack of adherence to PrEP could have explained the low prophylactic 
effect. Less efficacy in certain populations, such as heterosexual women, may be explained by a 
combination of noncompliance and also by the difference in tissue concentrations of PrEP. For 
these reasons, the importance of adherence should be stressed when prescribing PrEP. Despite the 
facts that PrEP is new to the medical community and its long-term efficacy is still being 
investigated, it should be considered as part of the preventative package offered to at-risk 
populations. In the future, research could reveal alternative drug options that would likely improve 
patient’s adherence to PrEP and could offer drugs with less adverse effects than those in the 
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